Dizan Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 17-11-2024
- Paid Up Capital ₹ 0.10 M
as on 17-11-2024
- Company Age 4 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -98.41%
(FY 2023)
- Profit 97.96%
(FY 2023)
- Ebitda 80.84%
(FY 2023)
- Net Worth -6.45%
(FY 2023)
- Total Assets -76.33%
(FY 2023)
About Dizan Lifesciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Patel Shivang, Danesh Desai, Zankhana Shah, and Three other members serve as directors at the Company.
- CIN/LLPIN
U24239GJ2020PTC116209
- Company No.
116209
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Sep 2020
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Dizan Lifesciences?
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Patel Shivang  | Director | 05-Sep-2020 | Current |
| Danesh Desai | Director | 05-Sep-2020 | Current |
| Zankhana Shah | Director | 05-Sep-2020 | Current |
| Jigar Chudasama | Director | 01-Dec-2020 | Current |
| Smitaben Shah | Director | 01-Dec-2020 | Current |
| Jayeshkumar Vaghela | Director | 01-Dec-2020 | Current |
Financial Performance of Dizan Lifesciences.
Dizan Lifesciences Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 98.41% decrease. The company also saw a substantial improvement in profitability, with a 97.96% increase in profit. The company's net worth dipped by a decrease of 6.45%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dizan Lifesciences?
Unlock access to Dizan Lifesciences's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Dizan Lifesciences?
Dizan Lifesciences has a workforce of 0 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dizan Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dizan Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
